Dailypharm Live Search Close

“Olumiant provides rapid AD symptom improvement"

By jung, sae-im | translator Kang, Shin-Kook

21.08.06 05:24:32

가나다라 0
[Interview] Professor Sang Wook Son (Department of Dermatology, Korea University Ansan Hospital)

Provides new treatment option to moderate-to-severe atopic dermatitis patients

Strength is in providing rapid improvement from Day 2… differentiated as an oral formulation


The introduction of JAK inhibitors in the field of moderate-to-severe atopic dermatitis (AD) treatment was like a welcome rain in the drought of treatment options in AD. In 2018, the approval of the biologic agent ‘Dupixent’ transformed the AD treatment paradigm, however, many patients still feel an unmet need existed due to the limited reimbursement conditions and high drug price.

JAK inhibitors are expected to widen the scope of treatment options for AD patients with features different than those offered by Dupixent. The first JAK inhibitor to receive approval for the AD indication was Eli Lilly’s ‘Olumiant (baricitinib)’

The treatment effect and safety of Olumiant were identified

jung, sae-im(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)